Taysha Gene Therapies Income Statement (2019-2026) | TSHA

Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
38.47M38.47M38.47M41.02M41.18M43.95M63.47M64.43M125.70M116.12M187.02M201.38M267.82M204.94M269.31M272.73M353.31M285.05M366.63M325.83M
Revenue & cost
Revenue (Quarter)
4.71M2.40M4.75M3.60M3.41M1.11M1.79M2.02M2.30M1.99M1.21M
Operating items
Research & Development (Quarter)
39.53M-91.03M38.18M23.51M16.77M12.71M12.51M19.79M11.79M-40.60M20.66M15.07M14.95M-49.68M15.56M20.14M25.75M-58.45M33.81M38.64M
Selling, General & Administrative (Quarter)
11.15M11.81M11.47M9.87M8.68M7.34M8.75M5.99M8.59M-20.73M7.08M7.34M7.90M6.63M8.16M8.60M8.28M8.83M9.68M12.15M
Other Operating Expenses (Quarter)
128.94M36.42M0.62M81.17M4.84M65.00M83.40M-3.43M
Operating Expenses (Quarter)
50.68M49.72M49.65M33.37M25.46M56.47M21.27M25.78M21.00M19.85M27.74M22.41M27.69M21.95M23.72M28.74M34.02M33.78M43.49M47.35M
Operating Income (Quarter)
-50.68M-49.72M-49.65M-33.37M-25.46M-53.97M-16.56M-23.38M-16.25M-16.25M-24.33M-21.30M-25.90M-19.93M-21.42M-26.75M-34.02M-28.30M-43.49M-47.35M
EBIT (Quarter)
-50.68M-49.72M-49.65M-33.37M-25.46M-53.97M-16.56M-23.38M-16.25M-16.25M-24.33M-21.30M-25.90M-19.93M-21.42M-26.75M-34.02M-28.30M-43.49M-47.35M
Non-operating items
Interest & Investment Income (Quarter)
1.11M1.92M1.69M1.44M2.11M1.70M1.33M1.86M3.17M2.87M2.59M2.33M
Other Non Operating Income (Quarter)
-0.00M-0.00M-0.01M-0.01M0.00M100.46M34.74M0.34M0.04M-0.08M-0.18M0.01M0.27M-0.04M0.74M-0.03M-0.09M
Non Operating Income (Quarter)
-0.51M-1.40M-0.67M0.03M-1.07M0.20M-1.06M-1.21M-100.84M63.99M0.27M0.37M0.37M1.15M-0.11M-0.13M1.29M0.45M1.08M0.71M
Net income details
EBT (Quarter)
-51.22M-24.55M-50.63M-34.12M-26.54M-56.01M-28.18M-55.53M-26.04M-15.66M-36.93M-29.45M-52.88M-23.43M-28.59M-51.17M-61.99M-25.44M-98.11M-159.39M
Profit After Tax (Quarter)
-51.19M-50.39M-50.32M-34.09M-26.53M-55.08M-17.62M-24.60M-117.09M47.74M-24.06M-20.93M-25.52M-18.79M-21.53M-26.88M-32.73M-27.85M-42.41M-46.64M
Income from Continuing Operations (Quarter)
-51.22M-24.55M-50.63M-34.12M-26.54M-56.01M-28.18M-55.53M-26.04M-15.66M-36.93M-29.45M-52.88M-23.43M-28.59M-51.17M-61.99M-25.44M-98.11M-159.39M
Consolidated Net Income (Quarter)
-51.22M-24.55M-50.63M-34.12M-26.54M-56.01M-28.18M-55.53M-26.04M-15.66M-36.93M-29.45M-52.88M-23.43M-28.59M-51.17M-61.99M-25.44M-98.11M-159.39M
Income towards Parent Company (Quarter)
-51.22M-24.55M-50.63M-34.12M-26.54M-56.01M-28.18M-55.53M-26.04M-15.66M-36.93M-29.45M-52.88M-23.43M-28.59M-51.17M-61.99M-25.44M-98.11M-159.39M
Net Income towards Common Stockholders (Quarter)
-51.19M-50.39M-50.32M-34.09M-26.53M-55.08M-17.62M-24.60M-117.09M47.74M-24.06M-20.93M-25.52M-18.79M-21.53M-26.88M-32.73M-27.85M-42.41M-46.64M
Additional items
EPS (Basic) (Quarter)
-1.35-1.34-1.32-0.85-0.65-1.25-0.28-0.38-0.930.41-0.10-0.09-0.10-0.08-0.08-0.09-0.09-0.09-0.12-0.13
EPS (Diluted) (Quarter)
-1.35-1.34-1.32-0.85-0.65-1.25-0.28-0.38-0.930.41-0.10-0.09-0.10-0.08-0.08-0.09-0.09-0.09-0.12-0.13
Shares Outstanding (Quarter)
38.00M37.65M38.17M40.14M40.94M43.95M63.26M64.24M125.70M116.12M231.25M232.82M267.82M250.13M269.31M297.99M353.31M319.71M366.63M369.04M
Shares Outstanding (Diluted) (Quarter)
38.00M37.65M38.17M40.14M40.94M43.95M63.26M64.24M125.70M116.12M231.25M232.82M267.82M250.13M269.31M297.99M353.31M319.71M366.63M369.04M
EBITDA (Quarter)
-50.68M-49.72M-49.65M-33.37M-25.46M-53.97M-16.56M-23.38M-16.25M-16.25M-24.33M-21.30M-25.90M-19.93M-21.42M-26.75M-34.02M-28.30M-43.49M-47.35M
Interest Expenses (Quarter)
0.54M-25.18M0.98M0.74M1.08M2.04M11.62M32.15M10.89M1.33M14.29M9.60M29.08M5.20M8.50M26.27M31.13M0.01M57.21M114.36M